The GH receptor is a member of the cytokine receptor superfamily. Studies in the 3T3-F442A mouse preadipocyte have shown that GH activates the Janus kinase (JAK2), the signal transducers and activators of transcription (STAT1, -3, and -5), and mitogen-activated protein (MAP) kinase. Our previous studies in the human IM-9 lymphocyte have shown that GH activates JAK2 and only STAT5 . In the studies presented here, we have investigated activation of the MAP kinase (MAPK) pathway in the IM-9 lymphocyte. Western blotting with antiphosphotyrosine-, anti-MAPK-, and anti-phospho-MAPK-specific antibodies as well in vitro kinase assays using a synthetic peptide substrate demonstrate that although GH (200 ng/ml) activates MAPK in 3T3-F442A cells (at 5 and 10 min of treatment), it does not activate MAPK in IM-9 lymphocytes at time points ranging from 5-60 min. Nevertheless, the phorbol ester phorbol 12-myristate 13-acetate (50 ng/ml) does activate MAPK in the IM-9 cell, and immunoprecipitation with specific antibodies indicates that this activation occurs through c-Raf-1. Although the 52-and 66-kDa forms of the adapter protein Shc are tyrosine phosphorylated in response to GH treatment in 3T3-F442A cells, we demonstrate that the predominant forms in IM-9 cells are the 52-and 46-kDa forms, and neither is tyrosine phosphorylated in response to GH. These studies further elucidate the differential signaling by GH in two cell types. (Endocrinology 139: 1965(Endocrinology 139: -1971(Endocrinology 139: , 1998 T HE GH receptor is a member of the hematopoietic receptor family, which includes receptors for the interleukins (interleukin
(200 ng/ml) activates MAPK in 3T3-F442A cells (at 5 and 10 min of treatment), it does not activate MAPK in IM-9 lymphocytes at time points ranging from 5-60 min. Nevertheless, the phorbol ester phorbol 12-myristate 13-acetate (50 ng/ml) does activate MAPK in the IM-9 cell, and immunoprecipitation with specific antibodies indicates that this activation occurs through c-Raf-1. Although the 52-and 66-kDa forms of the adapter protein Shc are tyrosine phosphorylated in response to GH treatment in 3T3-F442A cells, we demonstrate that the predominant forms in IM-9 cells are the 52-and 46-kDa forms, and neither is tyrosine phosphorylated in response to GH. These studies further elucidate the differential signaling by GH in two cell types. (Endocrinology 139: [1965] [1966] [1967] [1968] [1969] [1970] [1971] 1998) T HE GH receptor is a member of the hematopoietic receptor family, which includes receptors for the interleukins (interleukin-2, -3, -4, -5, -6, -7, -9, -11, -12, -13, and -15), colony-stimulating factors (granulocyte-macrophage and granulocyte colony-stimulating factors), erythropoietin, leukemia inhibitory factor, oncostatin M, ciliary neurotropic factor, thrombopoietin, and PRL (1) . These receptors share structural homology in their extracellular domain, dimerization of receptor subunits, and similarities in their intracellular signaling, particularly activation of the Janus kinase (JAK) family of intracellular kinases and the signal transducers and activators of transcription (STATs). GH, through dimerization of its receptor, activates predominantly JAK2 and STAT1, -3, and/or -5 (depending on cell type). In addition to activation of this pathway, signaling through insulin receptor substrate (IRS-1)/phosphatidylinositol-3-kinase (PI-3-kinase), mitogen-activated protein (MAP) kinase, and a pertussis toxin-sensitive G protein have been reported to be activated by GH under various conditions and in certain cell types (2) .
Although the general intracellular signaling pathways that are activated by GH have been characterized, our studies in the human IM-9 lymphocyte have demonstrated apparent differences in the pathways activated by GH compared with those reported in the well characterized 3T3-F442A mouse preadipocyte. As in 3T3-F442A cells, GH activates the tyrosine phosphorylation of JAK2 in the IM-9 lymphocyte (3). However, only STAT5 (not STAT1 or STAT3) is activated by GH in the IM-9 lymphocyte (4). Furthermore, activation of DNA binding, as seen by electrophoretic mobility shift assay analysis with the c-fos m67 sis-inducible element, is different in the two cell types (4) . In the data presented here, we demonstrate by Western blotting and in vitro kinase assay that GH does not activate MAP kinase (MAPK) in the IM-9 lymphocyte (as it does in the 3T3-F442A preadipocyte). The adapter protein Shc and the Raf kinase (known to be involved in GH signaling to the MAPK pathway) are also investigated.
Materials and Methods Reagents
Recombinant human GH (rhGH) and recombinant human interferon-␥ (IFN␥) were purchased from Genentech (San Francisco, CA). The enhanced chemiluminescence kit (ECL) was purchased from Amersham (Arlington Heights, IL). Polyclonal antiphosphotyrosine antibody has been described previously (5) . Horseradish peroxidase-conjugated, recombinant antiphosphotyrosine (RC20H), and polyclonal anti-Shc were obtained from Transduction Laboratories (Lexington, KY). Anti-MAPK (Erk2) was purchased from Upstate Biotechnology (Lake Placid, NY), and anti-phospho-MAPK was obtained from New England Biolabs (Beverley, MA). Anti-STAT5 (sc-835) and polyclonal anti-Raf (anti-A-Raf and anti-C-Raf-1) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Phorbol 12-myristate 13-acetate (PMA) was purchased from Sigma Chemical Co. (St. Louis, MO). Acrylamide, bisacrylamide, SDS, and prestained molecular mass standards as well as all tissue culture reagents were obtained from Life Technologies (Gaithersburg, MD). Except where noted, other reagents were either reagent or molecular biological grade from Sigma Chemical Co.
(University of Wisconsin). IM-9 cells were grown as suspension cultures in Corning T-150 flasks in a 37 C, 5% CO 2 incubator in MEM supplemented with nonessential amino acids, glutamine, and 10% FCS. 3T3-F442A cells were grown in DMEM-10% FCS on Corning T-75 flasks (Corning, Corning, NY). Cells were passaged every 3 days at 1:10 (IM-9) or 1:20 (3T3-F442A) dilution. After 3 days of growth, cells were preincubated in either MEM or DMEM containing 0.1% BSA, overnight or for 1 h at 37 C depending on the particular experiment. The next day, cells were pelleted and washed in 0.1% BSA-containing medium in the case of IM-9s, or medium was removed and new 0.1% BSA-containing medium was added in the case of 3T3-F442A cells. Cells were then treated with medium alone (control), 200 ng/ml rhGH, or 5 ng/ml PMA for various times at 37 C. At the end of this incubation, cells were washed in PBS and then lysed in lysis buffer which contained 150 mm NaCl, 5 mm EDTA, and 50 mm Tris, pH 7.4 and one of the following detergents (see details of each experiment): 1% Nonidet P-40, 1% Triton X-100, or 1% Triton X-100 and 1% deoxycholate. All lysis buffers contained the following protease and phosphatase inhibitors: 25 g/ml leupeptin, 0.076 trypsin inhibitor unit/ml aprotinin, 10 mm vanadate, and 0.2 mm phenylmethylsulfonylfluoride. Lysates were stored at Ϫ70 C until use. Upon thawing, lysates were microfuged (100,000 ϫ g, 10 min, 4 C), and resulting supernatants were analyzed as described below.
Western blotting
Lysates prepared as described above were mixed 1:1 with Laemmli buffer (6) and fractionated through a 7.5% polyacrylamide gel, electrophoretically transferred to nitrocellulose, and blotted as described previously (3). Blocking buffers were 0.15 m NaCl, 0.1% Tween-20, and 50 mm Tris, pH 8.0, and 3% BSA for the antiphosphotyrosine antibody or 5% nonfat dry milk for all other antibodies. Secondary antibodies were either donkey antirabbit or sheep antimouse conjugated to horseradish peroxidase, and antibody binding was detected using the ECL detection kit.
Immunoprecipitation
For Shc immunoprecipitation, cells were lysed in 1% Triton X-100 and 0.5% Nonidet P-40-containing lysis buffer. For Raf immunoprecipitation, cells were lysed in a 1% Nonidet P-40 lysis buffer (see above). Lysates were incubated with antibody overnight at 4 C. Protein A-agarose (Boehringer Mannheim, Indianapolis, IN) was added for an additional 1 h at 4 C. Agarose pellets were washed (three times) in detergent buffer, and then bound proteins were removed by boiling in 1 ϫ Laemmli buffer.
MAPK activity assay
Cells were treated with GH (200 ng/ml) or PMA (5 ng/ml) for 5 min at 37 C before incubations were terminated by aspiration of the medium. Cells were washed twice with 10 ml PBS (4 C) before being harvested in extraction buffer (50 mm ␤-glycerophosphate, pH 7.3; 1.5 mm EDTA; 1 mm benzamidine; 0.5 mm Na 3 VO 4 ; 1 mm dithiothreitol; 0.1 mm phenylmethylsulfonylfluoride; and 1 g/ml each of leupeptin, aprotinin, and pepstatin A). Samples were quickly frozen in liquid nitrogen and stored at Ϫ70 C. MAPK activity was measured in triplicate by the ability of cell extracts to phosphorylate threonine 669 of a synthetic peptide substrate, as reported previously (7) . Briefly, 5-20 l extract were incubated with 50 m ATP (containing 200 Ci/ml [␥-
32 P]ATP) in the presence and absence of 0.2 mm T669 for 10 min at 30 C. Reactions were terminated by spotting 25-l aliquots onto 2-cm 2 squares of P-81 paper and immersion in 150 mm phosphoric acid. Samples were washed four times with phosphoric acid and once with ethanol before being air-dried and counted for radioactivity. The protein content of lysates was determined using the Bio-Rad protein assay kit, and MAPK activity was calculated as picomoles of phosphate incorporated per mg protein.
Results are presented as the median and range. Differences in MAPK activity between control and treated cells were examined by nonparametric analysis using the Mann-Whitney U test.
Results
Human IM-9 lymphocytes and mouse 3T3-F442A preadipocytes were treated either with medium alone or with 200 ng/ml rhGH for 5 min, and lysates were prepared and analyzed by PAGE. After electrophoretic transfer to nitrocellulose, blots were probed first with antiphosphotyrosine and then with anti-MAPK antibodies. As shown previously, Fig.  1A demonstrates that tyrosine phosphorylation is activated in response to GH in both cell types (4, 8 -10) . GH stimulates the tyrosine phosphorylation of JAK2 (ϳ120 kDa), the GH receptor (the diffuse band above JAK2 in IM-9 cells and below JAK2 in the 3T3-F442A cells), and STAT proteins (ϳ93 kDa). In addition to the tyrosine-phosphorylated proteins discussed above, other laboratories have reported that GH treatment of 3T3-F442A cells results in the tyrosine phosphorylation and activation of MAPK (11) (12) (13) . To determine whether MAPK was activated by GH in IM-9 cells as well, lysates from IM-9 and 3T3-F442A cells were immunoblotted with an antibody specific for MAPK, which, at the concentration used, detects the 42-kDa form of MAPK. As seen in the control lanes of Fig. 1B , MAPK is detected in both IM-9 and 3T3-F442A cells. However, an upshift in molecular mass (indicating activation) occurs only in 3T3-F442A cells and not in IM-9 cells. This result is consistent with antiphosphotyrosine blotting from our original work in IM-9 cells, which failed to show a tyrosine-phosphorylated protein in the MAPK molecular mass range (14) .
To confirm the results presented above, we used the re- It has been shown previously by several laboratories that GH activates MAPK in the 3T3-F442A preadipocyte cell line in a time-dependent manner (11) (12) (13) . Thus, activation of the MAPK pathway in 3T3-F442A preadipocytes and in IM-9 lymphocytes was analyzed under the same treatment and Western blotting conditions. Both cell types were treated with 200 ng/ml rhGH for times ranging from 5-60 min. Furthermore, each cell type was also treated for these times with the phorbol ester PMA to demonstrate activation of the MAPK pathway through Ras/Raf. Figure 3 shows analysis of MAPK activation in 3T3-F442A preadipocytes using Western blotting with both antiphosphotyrosine (Fig. 3A) and anti-MAPK (Fig. 3B) . As reported by others (11) (12) (13) , activation of MAPK by GH was time dependent and, as seen by both antiphosphotyrosine and anti-MAPK blots, was evident at 5 and 10 min, but decreased by 30 min in the 3T3-F442A cells. Furthermore, a robust activation of MAPK occurred in response to PMA and lasted throughout the 30-min treatment period; in fact, all of the MAPK protein detectable by anti-MAPK blotting was activated to the slower mobility form (see Fig. 3B ).
We next tested the ability of GH to activate MAPK in IM-9 lymphocytes. Figure 4A shows antiphosphotyrosine blotting of lysates from IM-9 cells treated with GH for up to 60 min. Asshownpreviously,GHstimulatedthetyrosinephosphorylation of the GH receptor, JAK, and STAT proteins, and this stimulation occurred after 5 min of treatment and lasted for up to 30 min, but was obviously decreased by 60 min. However, we found that there was no protein in the MAPK molecular mass range that was tyrosine phosphorylated in response to GH at any of these time points. This lack of activation was even more obvious compared with that after treatment with PMA. A protein of the correct molecular mass for MAPK was clearly activated at all times of treatment with PMA (Fig. 4A, arrow) . Figure 4B shows immunoblotting of IM-9 lysates with the MAPK antibody; results different from those seen with 3T3-F442A cells were obtained. No shifted band indicative of activated MAPK was seen in any of the GH-treated samples (Fig. 4B ). These results demonstrate that   FIG. 2 . Phospho-specific MAPK antibody. In the top panel, 3T3-F442A cells (3T3) were pretreated overnight, and IM-9 cells were pretreated for 1 h in serum-free medium before treatment with 200 ng/ml rhGH for 5 min (3T3) or 10 min (IM-9). C, Control; G, rhGH treated. In the bottom panel, IM-9 cells were preincubated overnight in serum-free medium and then treated with medium alone (C), 200 ng/ml rhGH (G), 10 ng/ml IFN␥ (␥), or 50 ng/ml PMA (P) for 15 min. Cells were lysed in 1% Triton X-100 lysis buffer, as described in Materials and Methods, and analyzed by Western blotting with a phospho-specific MAPK antibody that recognizes catalytically active tyrosine-phosphorylated p42 and p44 MAPK (New England Biolabs). pMAPK indicates the phosphorylated form of MAPK. GH does not activate MAPK in the IM-9 cell during time points at which MAPK is activated in the 3T3-F442A preadipocyte and under conditions in which JAK2 and STAT5 are tyrosine phosphorylated. In the IM-9 samples treated with PMA, an upper band resulting in a doublet upon MAPK blotting indicated that MAPK was activated in IM-9 cells with this treatment. However, the MAPK protein that was detected in IM-9 cells was not completely activated to the phosphorylated form by PMA in the IM-9 cells as it was in the 3T3-F442A cells (compare Fig. 4B with Fig. 3B ).
To directly assess MAPK activity in these two cell types, in vitro kinase assays were performed using cell extracts from 5 min of treatment and a synthetic peptide corresponding to the sequence surrounding Thr 669 of the epidermal growth factor receptor, a substrate of MAPK (see Materials and Methods). As shown in Table 1 , both GH and PMA activated MAPK activity in 3T3-F442A cells when measured in this assay. In contrast, although PMA clearly activated MAPK activity in IM-9 cells, GH did not. In fact, the median activity was very comparable in the control and GH-treated extracts. Assays over a time range of 5, 10, 30, and 60 min of GH treatment showed no significant increase in MAPK activity, whereas PMA increased activity, with a peak at 5 min (data not shown). These activity results are consistent with the Western blotting results shown in Figs. 1-4 , supporting the conclusion that GH does not activate MAPK in the IM-9 lymphocyte, and that although PMA does activate MAPK in IM-9 cells, it is not activated to the extent that it is in 3T3-F442A cells.
A number of studies have indicated that GH activates the MAPK pathway through activation of the adapter proteins Shc and Grb2, leading to activation of Ras and Raf (18, 19) . We thus wanted to investigate the presence and activation of these proteins in the IM-9 cell. Figure 5 shows Western blotting and immunoprecipitation with isoform-specific Raf antibodies (anti-A-Raf and anti-C-Raf-1). Blotting indicated that both isoforms of Raf were present in IM-9 lymphocytes (see Fig. 5 , A and B, total lysates). Furthermore, a shift of the C-Raf band in the PMA-treated lane upon Western blotting of total lysates with anti-C-Raf indicated that it was activated Values are presented as the median and range (picomoles per mg protein).
a Control and GH are from 6 separate experiments; PMA treatment is from 5 separate experiments. There is a significant difference from control for both GH and PMA samples (P ϭ 0.02 and P ϭ 0.01, respectively).
b Control is from 15 experiments, GH is from 9 experiments, and PMA from 5 experiments. A significant increase in activity is seen in PMA-treated (P ϭ 0.02), but not GH-treated, cells. in response to this treatment (Fig. 5A) . In contrast, blotting with anti-A-Raf did not demonstrate a shift in this protein with treatment, suggesting that A-Raf was not activated (Fig.  5B) . Immunoprecipitation with isoform-specific antibodies also showed a shift of C-Raf (Fig. 5A ), but not A-Raf (Fig. 5B) , with PMA treatment, supporting the hypothesis that Raf (probably C-Raf in particular) is activated in response to PMA treatment (presumably through activation of PKC). Neither C-Raf nor A-Raf underwent an apparent increase in molecular mass in response to GH treatment.
There is evidence in 3T3-F442A cells that GH activates the MAPK pathway through tyrosine phosphorylation and activation of the adapter protein, Shc. Therefore, we compared the expression and tyrosine phosphorylation of Shc in IM-9 and 3T3-F442A cells. In Fig. 6A , immunoprecipitation followed by blotting with Shc antibody demonstrated that three forms of Shc were present in 3T3-F442A cells (66, 52, and 46 kDa), whereas IM-9 cells contained predominantly the 52-and 46-kDa forms of Shc (on overexposure, some signal at 66 kDa could be seen). Interestingly, in response to PMA treatment of 3T3-F442A cells, the 66-kDa form of Shc was shifted in apparent molecular mass, as seen by Shc blotting, but was apparently not tyrosine phosphorylated (as seen by antipTyr in Fig. 6B ). This shift may correspond to serine phosphorylation of 66-kDa Shc, as recently reported in response to insulin (see Discussion). Anti-pTyr blotting (Fig. 6B) showed that the 66-and 52-kDa forms of Shc in 3T3-F442A cells were tyrosine phosphorylated in response to GH, as described by others (18) . Furthermore, there were two tyrosine-phosphorylated bands seen at each molecular mass, suggesting further GH-stimulated modification (possibly a serine/threonine phosphorylation). Most importantly, neither the 52-nor 46-kDa Shc isoforms present in IM-9 cells were tyrosine phosphorylated in response to GH treatment, indicating that Shc is not tyrosine phosphorylated or activated, corresponding with the lack of MAPK activation by GH in these cells.
Discussion
Characterization of GH receptor signaling has demonstrated that GH is able to activate the JAK2 tyrosine kinase (and in some cases JAK1), the STAT transcription factors (1, 3, and 5), IRS-1, PI-3-kinase, and MAPK (2). Our studies in the human IM-9 lymphocyte have shown that GH stimulates the tyrosine phosphorylation of JAK2, the GH receptor, STAT5 (but not STAT1 and -3), and binding to the lactogenic hormone-responsive region (LHRR) but not to the sis-inducible element of the c-fos promoter (3, 4, 20) . In the studies presented here we have shown that although GH activates MAPK in 3T3-F442A cells, it does not stimulate this pathway in IM-9 cells. Western blotting as well as in vitro kinase assays showed that although GH stimulated MAPK in the 3T3-F442A cell, MAPK was not activated by GH in the IM-9 lymphocyte, even at time points at which JAK2, GH receptor, and STAT5 were tyrosine phosphorylated. These results suggest that the mechanism(s) responsible for blocking and/or turning off the MAPK signal from the GH receptor is activated in the IM-9 lymphocyte. Differential signaling in response to GH has also recently been reported by others. Chow et al. using an in vivo rat model have shown that although GH activates JAK2 and STAT5 in rat liver and skeletal muscle, IRS-1 and Shc are not activated (21) . Our work in primary human fibroblasts indicates that GH activates MAPK and DNA binding to the LHRR, but not the IFN response element or sis-inducible element and that the complex with the LHRR contains STAT1 and -5 (22, 23) . The mechanisms responsible for cell type-specific signaling in response to GH have yet to be fully elucidated.
As a means toward characterizing the MAPK pathway in IM-9 cells, we have demonstrated that the phorbol ester PMA is able to activate MAPK in these cells. Phorbol ester stimulation of MAPK is thought to occur through PKC, which activates the pathway at the level of Ras and/or Raf (15) (16) (17) 24) . Specific analysis of Raf isoforms in IM-9 cells indicated that C-Raf-1 was activated in response to PMA treatment. Therefore, these PMA studies suggest that the pathway from Ras/Raf to MAPK is functional and able to be activated in the IM-9 cell. We found that PMA activation of MAPK occurred to a greater extent in 3T3-F442A cells than in IM-9 cells. This difference could be seen both by Western blotting as well as by in vitro kinase assays and suggests that a negative regulatory mechanism may be constitutively active in the IM-9 cell. One such mechanism would involve a phosphatase acting on the MAPK pathway. Along these lines, we are currently investigating the potential role of the serine/threonine phosphatase PP2A in the MAPK pathway in IM-9 cells.
The adapter protein Shc has been shown to become activated by a number of cytokines. Shc, through binding to the cytokine receptor/JAK complex becomes tyrosine phosphorylated, leading to the binding of Grb2 and the activation of Sos, Ras, Raf, MEK, and MAPK (25, 26) . Three isoforms of Shc have been identified (66, 52, and 46 kDa), and their regulation, expression, and activation are just now beginning to be elucidated (27) . Both serine and tyrosine phosphorylations of Shc isoforms have been shown to be involved in their regulation. For example, serine as well as tyrosine phosphorylations of 52-and 46-kDa Shc isoforms have been reported in response to erythropoietin (28 shc in CHO (Chinese hamster ovary) and 3T3-L1 adipocytes (29) . A recent report suggests a negative regulatory role for the 66-kDa form of Shc in epidermal growth factor stimulation of the MAPK pathway (30) . All three isoforms of Shc have been identified in the 3T3-F442A preadipocyte and have been shown to be tyrosine phosphorylated in response to GH treatment, leading to the binding of Grb2, which through Sos and Raf leads to activation of the MAPK pathway (18, 19) . We found that the 52-and 46-kDa forms of Shc are the predominant forms present in the IM-9 cell, similar to other hematopoietic cell types (27) . Furthermore, GH stimulation of these cells does not activate tyrosine phosphorylation of either of these forms as it does in 3T3-F442A cells. PMA treatment did not have any apparent effect on the 52-and 46-kDa Shc isoforms in IM-9 cells. A long exposure of the Shc blot from IM-9 lysates resulted in some detection of a 66-kDa band. The role of such a low level of 66-kDa Shc in IM-9 cells is not known; however, PMA did cause an increase in the apparent molecular mass of this band. Furthermore, PMA treatment resulted in an obvious shift in the molecular mass of the 66-kDa form in 3T3-F442A cells. This PMA-induced shift in the 66-kDa form was not due to tyrosine phosphorylation and, thus, may have been due to a serine phosphorylation similar to that reported in response to insulin in 3T3-L1 cells (see above). However, the potential role of a serine phosphorylation of p66 shc in the PMA stimulation of MAPK is not known. Therefore, the Shc adapter protein is apparently differentially expressed and regulated in IM-9 and 3T3-F442A cells. The mechanism for this divergence is not understood, but may involve cell type-specific expression and/or activation of phosphatases and kinases involved in the tyrosine and/or serine phosphorylation of Shc or other, as yet unidentified, adapter proteins.
Recent studies have indicated that the Shc/Grb2/Sos/ Ras/Raf pathway is not the only pathway that leads to activation of MAPK in response to GH. Like other cytokines, such as the IFNs (␣ and ␥) and the interleukins (2, 4, 7, and 15), GH has been shown to stimulate the tyrosine phosphorylation of IRS-1, leading to the association of the PI-3-kinase (31) (32) (33) (34) . More recently, Anderson et al. have shown that GH increases PI-3-kinase activity in 3T3-F442A cells and that a PI-3-kinase inhibitor (wortmannin) attenuates the GH-stimulated MAPK activity in these cells (35) . Studies using antisense oligodeoxynucleotides provide evidence for the role of a specific isoform of PKC (PKC␦) in the activation of the MAPK pathway by GH in the 3T3-F442A preadipocyte (36) . However, inhibition of either PKC or PI-3 kinase only partially inhibits GH stimulation of MAPK (35, 36) . Thus, at least in the 3T3-F442A preadipocyte, there may be two pathways by which GH activates MAPK, one involving Shc/Grb2 and one involving IRS-1/PI-3-kinase/PKC␦. Whether these pathways converge and whether they are involved in MAPK activation by GH in all cell types are not clear. We are currently investigating the potential role of the IRS-1/PI-3 kinase/PKC pathway in GH signaling in IM-9 cells.
In summary, our studies in the human IM-9 lymphocyte continue to demonstrate cell type-specific signaling by the GH receptor. Our initial work in IM-9 cells characterizing GH-stimulated tyrosine phosphorylation indicated that GH did not stimulate MAPK in these cells (14) . The studies presented here specifically address the MAPK pathway and demonstrate that GH does not stimulate MAPK activity in these cells. Whether failure of GH to activate this pathway is a particular characteristic of IM-9 cells, a transformed cell line derived from a human myeloma, or whether it represents GH signaling in the lymphocyte cell type in general remains to be determined. Studies by others have demonstrated a stimulatory effect by GH on IM-9 cell growth under certain serum conditions (37, 38) . Together with our studies, these results suggest that GH activation of growth in these cells occurs without activation of the MAPK pathway. Therefore, the IM-9 lymphocyte continues to provide a model for characterizing differential signaling from the GH receptor and the roles of individual signaling pathways.
